Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Data in the Context of Comparable Gene, Protein, and Lipid Data (U01)

RFA-RM-16-021
Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Data in the Context of Comparable Gene, Protein, and Lipid Data (U01)
Department of Health and Human Services
National Institutes of Health

successful-grant-writing-strategies-for-an-r-award-15-638

Research Objectives and Scope

The analysis and integration of carbohydrate and glycoconjugate data is a complex challenge. Present computational and informatics technologies for carbohydrate analysis are decades behind those developed for nucleic acids and proteins. Like other aspects of glycobiology, progress in glycoinformatics is sporadic and fragmented. The resulting tools are primitive, and poorly integrated, and adoption by non-specialists has been slow. Certain glycoinformatics tools, such as glycan structure databases, have been developed. These databases, however, are limited and balkanized, and are not matched with tools for interrogating the databases in meaningful ways. They are also not well-integrated with databases for proteins or genomic information. Other classes of glycoinformatics tools are in their infancy, or entirely lacking. Examples include algorithms for spectral interpretation to support glycoconjugate structure determination, or interpretation of glycan array binding data.

Recent community-led efforts to arrive at standardization of glycan nomenclature as expressed in databases, interoperability of databases, and reporting of experimental metadata have been promising. Two important features of these recent efforts are: (1) they have been inclusive, community-driven projects, and (2) they have focused on preserving the utility of the tools already created.  Efforts to bring glycoinformatics up to the current state of the art available for the other classes of biological macromolecules must be grounded in a clearly articulated vision for addressing the significant challenges confronting the field, and facilitate participation of many independent research groups. The project should create an environment that enables current and future software developers to join this effort with a clear understanding of the framework within which their contributions will be most effective.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-RM-16-021
Funding Opportunity Title: Data Integration and Analysis Tools: Accessible Resources for Integration and Analysis of Carbohydrate and Glycoconjugate Data in the Context of Comparable Gene, Protein, and Lipid Data (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:  
Expected Number of Awards: 1
CFDA Number(s): 93.310 — Trans-NIH Research Support
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 16, 2016
Last Updated Date: Sep 16, 2016
Original Closing Date for Applications: Nov 28, 2016  
Current Closing Date for Applications: Nov 28, 2016  
Archive Date: Dec 29, 2016
Estimated Total Program Funding: $2,000,000
Award Ceiling: $1,500,000
Award Floor:

Eligibility

Eligible Applicants: City or township governments
Special district governments
Public housing authorities/Indian housing authorities
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
State governments
Independent school districts
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
County governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The Common Fund Program – Accelerating Translation of Glycoscience: Integration and Accessibility – aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-16-021.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Limited Competition for the Continuation of the Hepatitis B Research Network Clinical Centers (U01)

RFA-DK-16-512
Limited Competition for the Continuation of the Hepatitis B Research Network Clinical Centers (U01)
Department of Health and Human Services
National Institutes of Healthhepatitis-b

Section I. Funding Opportunity Description

In prior funding cycles, the HBRN has developed and initiated the following protocols: an Adult and a Pediatric Cohort studies; the Adult Immune Active study; an Adult and a Pediatric Immune Tolerant studies.  Additional ancillary studies have been developed and implemented that focus on specific aspects of various clinical scenarios, approaches to assessment, or complications that are associated with hepatitis B.  In addition to the clinical studies in progress noted above, the HBRN has developed a biospecimen repository consisting of over 340,600 adult and 10,700 pediatric plasma and sera samples; and 1372 adult and 182 pediatric DNA specimens; along with detailed clinical database.

The HBRN is currently composed of 15 adult and 7 pediatric clinical sites throughout North America and a Data Coordination Center through 10 individual U01 Cooperative Agreements.

The HBRN Clinical Centers, which will be supported through this FOA, are  primarily charged with completing and analyzing the various clinical studies currently underway and for the future, to consider novel treatment trials for chronic hepatitis B and delta hepatitis; and to exploit translational research opportunities with the vast collection of biospecimens in the repository .

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-DK-16-512
Funding Opportunity Title: Limited Competition for the Continuation of the Hepatitis B Research Network Clinical Centers (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:  
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:  
Expected Number of Awards:  
CFDA Number(s): 93.847 — Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Aug 18, 2016
Last Updated Date: Aug 18, 2016
Original Closing Date for Applications: Dec 19, 2016  
Current Closing Date for Applications: Dec 19, 2016  
Archive Date: Jan 19, 2017
Estimated Total Program Funding: $7,000,000
Award Ceiling:  
Award Floor:

Eligibility

Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Faith-based or Community-based Organizations; Only the current HBRN awardees are eligible to apply to this FOA. Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See FOA for Eligibility Details

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement (FOA) is to continue the Hepatitis B Research Network Clinical Centers with a focus on the promotion of translational research on hepatitis B focusing upon elucidating the pathogenesis and natural history and developing means of treatment and control.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-512.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24)

RFA-AA-17-005
Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24)
Department of Health and Human Services
National Institutes of Health

logo-NCANDA

Objective and Organization of the NCANDA Consortium  

The primary objective of NCANDA is to address the following research questions:  1) what are the effects of both long and shorter-term adolescent alcohol exposure on the developing human brain; 2) what is the effect of timing, dose, and duration of alcohol exposure on brain development;  3) to what extent do these effects resolve or persist; 4) understand how key covariates factor into alcohol’s effects on the brain; and 5) potentially identify early neural, cognitive, and affective markers that may predict alcohol abuse and dependence and onset or worsening of mental illness during adolescence and into adulthood.

The organization of the NCANDA consortium consists of an overall Administrative Resource, a central Data Analysis Resource, and research project sites:

The NCANDA Administrative Resource (RFA-AA-17-004) coordinates the activities of the nation-wide consortium and is responsible for the development, tracking, and reporting of performance metrics from the research project sites and for the overall consortium.

The NCANDA Data Analysis Resource (this FOA) has responsibility for the standardization, storage, and analysis of the data acquired by the research project sites of the consortium.

The NCANDA Research Project Sites (RFA-AA-17-003) have responsibility for the acquisition of data according to the standard protocol for the nation-wide consortium and for the development of special research projects related to their expertise and interests that complement and support the overall objectives of the consortium.

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-AA-17-005
Funding Opportunity Title: Limited Competition for the Continuation of the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA) Data Analysis Resource (U24)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards: 1
CFDA Number(s): 93.242 — Mental Health Research Grants
93.273 — Alcohol Research Programs
93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Posted Date: May 31, 2016
Last Updated Date: May 31, 2016
Original Closing Date for Applications: Nov 09, 2016  
Current Closing Date for Applications: Nov 09, 2016  
Archive Date: Dec 10, 2016
Estimated Total Program Funding: $5,000,000
Award Ceiling: $600,000

Eligibility

Eligible Applicants:
Special district governments
Native American tribal governments (Federally recognized)
For profit organizations other than small businesses
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
County governments
Independent school districts
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
City or township governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; See full text of the funding opportunity for complete details.

Additional Information

Agency Name: National Institutes of Health
Description: This limited competition Funding Opportunity Announcement (FOA) is to support the continuation of the Data Analysis Resource for the National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA). Only the current NCANDA Data Analysis Resource awardee is eligible to apply in response to this FOA. The NCANDA Data Analysis Resource has responsibility for the standardization, storage, and analysis of the data acquired by the research project sites of the nation-wide consortium to study the impact of alcohol drinking on brain structure and function during adolescence and into early adulthood. RFA-AA-17-004 will support continuation of the NCANDA Administrative Resource and RFA-AA-17-003 will support the continuation of the research projects sites within the consortium.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-17-005.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

For more grant opportunities with this FOA please visit: http://www.grants.gov/web/grants/view-opportunity.html?oppId=284252

 

NeuroNEXT Clinical Trials (U01)

PAR-16-155
NeuroNEXT Clinical Trials (U01)
Department of Health and Human Services
National Institutes of Health

Scope of the Program

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies.  Applications for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it is expected to be of benefit in ameliorating a specific aspect of the disease. Neurologic diseases chosen for study must fall within the primary responsibility of NINDS (http://www.ninds.nih.gov/disorders/disorder_index.htm).

Examples of appropriate studies under this FOA include, but are not limited to, those designed to:

  • Evaluate and optimize the dose, formulation, safety, tolerability or pharmacokinetics of an intervention in the target population.
  • Evaluate whether an intervention produces sufficient evidence of short-term activity (e.g., biomarker activity, pharmacodynamic response, target engagement, dose-response trends) in a human “proof of concept” trial.
  • Select or rank the best of two or more potential interventions or dosing regimens to be evaluated in a subsequent trial, based on tolerability, safety data, biological activity, or preliminary clinical efficacy (e.g., futility trials).
  • Evaluate biological activity relative to clinical endpoints.
  • For medical devices, in addition to providing initial clinical safety data, appropriate studies are those that inform the next phase of development, usually by finalizing the device design, establishing operator technique, and/or finalizing the choice of study endpoints for the design of a pivotal clinical trial.

Studies in stroke prevention, treatment and/or recovery are not appropriate for inclusion in  NeuroNEXT. All multi-site stroke studies will be conducted in the NINDS-funded stroke trials network (http://www.ninds.nih.gov/research/clinical_research/NINDS_stroke_trials_network.htm).

neurology

 

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-16-155
Funding Opportunity Title: NeuroNEXT Clinical Trials (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Posted Date: Mar 28, 2016
Last Updated Date: Mar 28, 2016
Original Closing Date for Applications: Aug 03, 2017  
Current Closing Date for Applications: Aug 03, 2017  
Archive Date: Sep 03, 2017
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants:
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
City or township governments
Public housing authorities/Indian housing authorities
Special district governments
County governments
Private institutions of higher education
Small businesses
Native American tribal governments (Federally recognized)
Independent school districts
Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-16-155.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

Department of Health and Human Services LogoPAR-15-297
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
Department of Health and Human Services
National Institutes of Health

Document Type: Grants Notice
Funding Opportunity Number: PAR-15-297
Funding Opportunity Title: Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.393 — Cancer Cause and Prevention Research
Cost Sharing or Matching Requirement: No

Posted Date:Jul 14, 2015

Creation Date:Jul 14, 2015

Original Closing Date for Applications:Aug 15, 2018 

 Current Closing Date for Applications:Aug 15, 2018  

Archive Date:Sep 15, 2018

Estimated Total Program Funding:

Award Ceiling:

Award Floor:
Eligibility

Eligible Applicants:
County governments
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
City or township governments
For profit organizations other than small businesses
Private institutions of higher education
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Small businesses
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-15-297.html
Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)

RFA-HL-16-010
Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)
Department of Health and Human Services
National Institutes of Health

Posted Date: Jul 15, 2015
Creation Date: Jul 15, 2015
Original Closing Date for Applications: Nov 12, 2015  
Current Closing Date for Applications: Nov 12, 2015  
Archive Date: Dec 13, 2015
Estimated Total Program Funding: $4,851,000
Award Ceiling:
Award Floor:

 

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-16-010
Funding Opportunity Title: Sickle Cell Disease Implementation Consortium (SCDIC): Using Implementation Science to Optimize Care of Adolescents and Adults with Sickle Cell Disease (U01)
Opportunity Category: Discretionary
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
CFDA Number(s): 93.839 — Blood Diseases and Resources Research
Cost Sharing or Matching Requirement: No

Eligibility

Eligible Applicants:
Others (see text field entitled “Additional Information on Eligibility” for clarification)
County governments
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
Public and State controlled institutions of higher education
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
City or township governments
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
State governments
Independent school districts
Native American tribal governments (Federally recognized)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Additional Information

Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) solicits applications as part of the Sickle Cell Disease Implementation Consortium (SCDIC) to support Clinical Sites to improve the health and well-being of adolescents and adults with sickle cell disease (SCD) in the US through the development of multi-modal, multi-sector interventions aimed at improving the rate at which patients with SCD receive routine primary care. Applications that consist of multi-disciplinary teams of personnel from community and academic health-care institutions are highly sought.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-16-010.html